depression. The primary outcome is linkage to HCV care (yes/no) within 60 days. In this protocol paper, we describe the first clinical trial to examine the effects of a nurse case management intervention to improve the HCV care continuum among people coinfected with HIV/HCV in the era of all-oral HCV treatment. We describe our work in progress, challenges encountered, and strategies to engage this hard-to-reach population.
and much less toxic in this population (Thomas, 2014) . With new advances in treatment, we have the opportunity to cure HCV in at least 94-97% of people with the disease, including PLWH (Naggie et al., 2015; Sulkowski et al., 2015; Wyles et al., 2015 Wyles et al., , 2017 . However, medication availability and the promise of HCV cure alone are not sufficient to engage all people in care. Challenges across the HCV continuum of care persist, especially in the HIV-co-infected population, indicating a need for interventions to minimize barriers to linking HIV/HCV co-infected patients into HCV care and providing support for this population to succeed in treatment (Cachay et al., 2014) .
The greatest gap in the HCV care cascade in the United States falls between diagnosis and treatment initiation (Cachay et al., 2014; Linas et al., 2014; Yehia, Schranz, Umscheid, & Lo Re, 2014) . As few as half of those with an HCV diagnosis are linked to HCV care (Yehia et al., 2014) ; in one multi-site study of 1,303 HIV/HCV co-infected patients linked to care, researchers found that only half were prescribed DAAs and 43% started a DAA between 2014 and 2017 (Jayaweera et al., 2018) .
Some of this gap in linkage to care and treatment initiation may be attributed to the low perceived threat of HCV and, as such, a low perceived need for HCV treatment and limited motivation (Harris & Rhodes, 2013; Yap et al., 2014) . Likewise, U.S. adults with HCV have reported difficulty in accessing HCV-treating providers and navigating the healthcare system (Zickmund, Campbell, Tirado, Zook, & Weinrieb, 2012) . In particular, with few overt symptoms, HCV is a "silent epidemic," often taking a lower priority among PLWH and their providers compared to other comorbidities (Alavi et al., 2013; Reiberger et al., 2011; Treloar, Newland, Rance, & Hopwood, 2010) , whereas HIV poses a greater perceived threat and a more imminent one (Munoz-Plaza et al., 2008; Wagner et al., 2009 ).
The low perceived threat of HCV is exacerbated by a lack of knowledge about HCV and available therapies (Coupland, Day, Levy, & Maher, 2009; Treloar, Hull, Dore, & Grebely, 2012; Zickmund et al., 2012) . HCV treatment initiation is associated with greater HCV knowledge (Grebely et al., 2011) , and lack of knowledge is a selfreported barrier to starting HCV treatment in up to 78 percent of patients (Alavi et al., 2013; Mehta et al., 2008) . It is important to note that peer networks facilitate an exchange of 42% of HCV-related information (Watson et al., 2007) , yet this peer pipeline can also focus on the negative effects of treatment, many of which have been eliminated with newer DAA-based regimens (North, Devereaux, Pollio, Hong, & Jain, 2014; Treloar et al., 2012; Zickmund et al., 2012) . Clearly, interventions to increase HCV knowledge, motivation, and access are needed to improve linkage to HCV care.
Prior interventions to promote the care continuum have included a variety of approaches with some success. For example, brief HCV education alone has been shown to result in a statistically significant increase of 14-25% in knowledge and linkage to HCV care (Chen et al., 2013; Gupta, Romney, Briggs, & Benker, 2007; Surjadi, Torruellas, Ayala, Yee, & Khalili, 2011; Tyler et al., 2014) . Similarly, nurse case management and care coordination have also been shown to improve linkage to HIV or HCV care by up to 30% (Craw et al., 2008; Gardner et al., 2005; Tyler et al., 2014) . Reminder systems using text and phone messages have also been effective strategies in increasing linkage to HIV care and substance use services in combination with other interventions, but have not been tested in the context of HCV care (Farmer, Brook, McSorley, Murphy, & Mohamed, 2014; Finitsis, Pellowski, & Johnson, 2014; van Velthoven, Brusamento, Majeed, & Car, 2013 ). Yet, a critical gap in the existing approaches is that few linkage to care studies target HCV; the majority of evidence comes from similar populations, including PLWH and people with substance use disorders. Those that are targeted toward HCV were conducted prior to the era of DAAs, often excluding persons with mental illness, substance use, or HIV co-infection.
In addition, HIV-HCV drug interactions will exist for up to 88% of PLWH (Patel et al., 2015) . Because cure rates are now similar between HCV mono-and HIV/HCV co-infected individuals, the only difference in management of HCV in PLWH is the need to address drug interactions (American Association for the Study of Liver Diseases & Infectious Diseases Society of America, 2018) . A large proportion of PLWH who are initiating HCV treatment will have to modify their HIV treatment regimen to accommodate these drug-drug interactions, but modifying HIV treatment regimens adds a further delay and deters PLWH from starting HCV treatment, as well as negatively impacting quality of life and increasing HIV symptom burden (Sherr et al., 2007) .
Moreover, HCV cure rates may be lower in persons who switch antiretroviral therapy (ART) to accommodate DAAs (Falade-Nwulia et al., 2017) . The addition of care coordination for ART modification may address this important new barrier for PLWH. To our knowledge, no published interventions to date have been designed to support ART modifications to accommodate HIV/HCV drug interactions.
The Care2Cure intervention was designed to address these gaps by testing comprehensive, multi-component nurse case management to improve the HCV care continuum among vulnerable HIV coinfected adults with HCV. The aims of the Care2Cure Study are to: (i) test whether a nurse case management intervention will increase linkage to HCV care among persons with HIV/HCV co-infection compared to enhanced usual care; and (ii) determine if a nurse case management intervention will decrease time to HCV treatment initiation among persons with HIV/HCV co-infection compared to enhanced usual care. In this paper we describe the protocol of the randomized, single blinded, controlled trial. The SPIRIT Statement checklist was adhered to in reporting this intervention protocol.
| METHODS

| Study aim and design
The Care2Cure study is designed to evaluate the preliminary efficacy of a standardized nurse case management intervention to improve the HCV care continuum among PLWH in a randomized controlled trial.
PLWH who are co-infected with chronic HCV and not engaged in HCV care are randomized to enhanced usual care or usual care plus HCV nurse case management (NCM) and followed for 6 months. After baseline assessment, participants are randomly assigned to the intervention arm in a 1:1 allocation using a block randomization scheme. Participants are evaluated at 60 days for linkage to care and at 6 months for time to treatment initiation. We hypothesize that (i) a higher proportion of participants in the intervention arm will attend an appointment for HCV care within 60 days; and (ii) participants in the intervention arm will have decreased time to HCV treatment initiation compared to participants in the enhanced usual care arm. This study protocol has been approved by the IRB of Johns Hopkins Medicine and is registered on ClinicalTrials.gov (NCT02707991). An integrated study flow and conceptual framework is detailed in Figure 1 .
The NCM intervention development was guided by Andersen's Behavioral Model of Health Services Use. Initially developed in the 1960s, this model explains the conditions that facilitate or impede utilization of health care (Andersen, 1995) . The model posits that a person's use of health services is a function of predisposing factors, perceived and actual need for care, and enabling or impeding resources. Predisposing characteristics, such as age, sex, race, ethnicity, substance use, and comorbidities, are not easily modified.
But perceived need, according to Andersen, can be changed through education; the greater the perceived and actual threat, the more likely one is to use services. Andersen also suggests that enabling resources can be influenced by interventions at the system, provider, and patient level. The more enabling resources one has, the greater the likelihood of healthcare utilization. We hypothesize that enabling resources for the uptake of HCV care among PLWH may include patient navigation, appointment reminders, and ART modification support, all addressed by nurse case management in the Care2Cure intervention.
Andersen's model has been applied previously to explain HCV and HIV health care utilization patterns and was used to inform the intervention components of the Care2Cure study (Henry, Goetz, & Asch, 2012; Holtzman et al., 2015; Mehta et al., 2005; Rapp et al., 2008) . Interventions that increase perceived need, minimize barriers, and maximize resources have the potential to improve the HCV care cascade for PLWH.
| Study setting
The Care2Cure Study is being conducted at the Johns Hopkins Hospital HIV clinic, which is part of the Bartlett Specialty Practice in Baltimore, Maryland. This is a hospital-based outpatient infectious disease clinic that provides both HIV primary care and HCV specialty care. The HIV practice cares for approximately 3,500 patients per year.
The clinic serves a primarily adult, urban population, with approximately 75% of patients being African American. The average age of clinic patients is 48 years (Lesko, Lau, Chander, & Moore, 2018; Moore, 1998) . Approximately 50% of patients with HIV are co-infected with HCV. The Bartlett Viral Hepatitis Practice, staffed with hepatologists and viral hepatitis-focused infectious disease physicians and nurse practitioners, is also part of the broader Bartlett Specialty Practice.
| Sample size and eligibility criteria
Seventy participants will be enrolled, with 35 in each treatment arm. In prior studies testing the intervention components in similar populations, including PLWH and/or substance use disorders, researchers found an improvement in linkage to care of 18-30% (Craw et al., 2008; Gardner et al., 2005; Masson et al., 2013; Rapp et al., 2008) . At the time of study initiation, 40% of new HCV Practice appointments were attended by patients (i.e., 60% no-show rate). We assume that we will find an improvement in linkage to care of at least 30% in the context of HCV (i.e., 70% attendance in the NCM group compared to 40% attendance in the enhanced usual care group). Using these figures and an alpha of 0.05, an estimate of the total sample size required to achieve 80% power is 33 per group, or a total of 66 participants (G*Power 3.1.9.2). Therefore, a sample size of 35 participants in each group should be adequate to detect the difference of interest in proportion of linkage to care for the primary aim. Participants are then referred to the usual clinic appointment checkout process. It is important to note that the clinic relocated during the course of this study, slightly changing the check-out process. For the first 9 months of enrollment, patients in the clinic returned to the front desk or checkout area with a billing page and printed appointment referrals if applicable. The administrative staff closed the appointment encounter and gave the patient a phone number for the Johns Hopkins Hospital central scheduling service to schedule referral-based appointments. Patients were responsible for calling central scheduling to set up the specialty appointment. In the new clinic, all encounters are handled electronically; the patient still goes to a checkout area to end an appointment, and the clinic staff reviews referrals and closes the appointment. The clinic procedure is to assist the patient to schedule any follow-up appointments indicated in the electronic record, although specialty referral-based appointments are often left unscheduled and therefore the patient is responsible for calling central scheduling to set up a specialty appointment. When an appointment is scheduled at this health system, all patients receive an automated appointment reminder call 2 days before the scheduled appointment.
Patients at the Bartlett Specialty Practice have access to HIV nurse case managers and Ryan White-funded social workers, similar to many HIV care settings. Participants in the enhanced usual care arm will continue to have usual access to these services. Per the Bartlett Specialty Practice standard care protocol, once a prescription is written for HCV treatment, the assigned HIV nurse case manager will work with the patient to coordinate HCV care; however, HIV nurse case managers are not directly involved in HCV care until after prescription for HCV treatment is written, which is the gap our NCM intervention seeks to fill.
| Experimental group-Usual care plus HCV NCM
The NCM intervention components by intervention phase (Phase 1:
Linkage to care and Phase 2: Treatment initiation) are outlined in Table 1 .
Phase 1: Linkage to care
This phase of the intervention is hypothesized to increase the proportion of participants who link to HCV care through NCM consisting of nurse-initiated referral, strengths-based HCV education, patient navigation, and HCV appointment reminders.
Nurse-initiated referral The nurse case manager initiates an HCV referral for participants randomized to the intervention group via the electronic health record or in-person conversation with the provider. This cues the HIV provider to submit the referral to HCV specialty care and minimizes the barrier of non-referral by the provider.
Strengths-based education Participants receive brief strengthsbased HCV education (Gottlieb, 2014) . Strengths-based education can improve knowledge and motivation to achieve health-related goals among PLWH (Craw et al., 2008; Gardner et al., 2005; Gottlieb, 2014) . The nurse case manager helps participants identify their strengths within the context of engaging in HCV care, including social support and engagement in HIV primary care (Fusfeld et al., 2013; Grebely et al., 2011) . HCV education topics include transmission, symptoms, treatment, and risk reduction, with a focus on the fact that there is a cure. Education is standardized and guided by a study-developed "Hepatitis C Basics" patient education handout.
Study participants also identify barriers to linkage to care and form a plan with the nurse case manager to minimize these barriers; this may include referrals to benefits counseling, substance use or mental health services, and/or an HCV support group called the "Cure Club" (Masson et al., 2013) . Table 12 (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2017).
The table serves as a decision-making aid for the HIV provider to modify the ART regimen if needed. The research nurse case manager coordinates an ART modification appointment with the participant's primary HIV provider as needed so the patient does not wait the usual 3-6 months until the next regularly scheduled HIV primary care visit.
| Fidelity
Several mechanisms are in place to ensure the intervention is delivered as planned. A detailed protocol and standard operating procedure manual that clearly specify the intervention components are available to the interventionist. Checklists have been developed for each interaction with a study participant to ensure consistency, and handouts are used to guide the intervention components. All study team members were trained and observed for adherence to the protocol. To minimize potential bias due to the interventionist's involvement in every step of the research, a study team member who is blinded to randomization collects medical record data for the outcome variables at 60 days and 6 months.
| Measures
Three types of study assessments are collected: (i) baseline data (including a self-report questionnaire and medical record review); (ii) monthly healthcare utilization logs (via the medical record); and (iii) outcome data (at 60 days and 6 months via the medical record). All study assessments are conducted by trained study staff. The baseline assessment is collected in the clinic after consent and before the participant is randomized to a study arm. Sixty-day and 6-month assessments are collected from the participants' electronic medical record by study staff who are blind to treatment allocation.
| Baseline characteristics
The baseline characteristics questionnaire used in the Care2Cure study includes demographics (age, race, ethnicity, gender), education and employment status, income and financial strain, self-reported health history, and substance use in the past 6 and 12 months. The current study team has used this questionnaire for a prior study in the same setting (Farley et al., 2017) . Questions have been added or removed as applicable to this study and patient population. In addition to these baseline characteristics, validated instruments to assess HCV knowledge, depression, and alcohol use are also administered at baseline.
Hepatitis C knowledge
The 19-item Brief Hepatitis C Knowledge Scale (Cronbach's α = 0.87) is administered to measure HCV knowledge (Balfour et al., 2009 ). The
Brief HCV Knowledge Scale is a unidimensional measure comprising a comprehensive list of items designed to address the main aspects of HCV knowledge: prevention, risk reduction, transmission, and treatment. It was designed and tested on a diverse sample of patients, health care workers, and students with varying socioeconomic and demographic backgrounds. It has a simple true/false scoring system with a total score range of 0-19.
Depression
The Patient Health Questionnaire (PHQ-9; Cronbach's α = 0.89) is used to measure depression, which can be associated with engagement in care (Kroenke, Spitzer, & Williams, 2001) . The PHQ-9 is scored 
Alcohol use
The Alcohol Use Disorders Identification Test (AUDIT) is administered to any participant who reports any alcohol use in the past 6 months on the baseline characteristics questionnaire (Babor, Higgins-Biddle, Saunders, Monteiro, & Dependence, 2001 ). The AUDIT consists of 10 items about recent alcohol use, alcohol dependence, symptoms, and alcohol-related problems. It was first developed in 1989 and has been validated in diverse international samples. The internal consistency reliability has been reported from 0.83 (Hays, Merz, & Nicholas, 1995) to the mid-0.90s (Babor et al., 2001) . In a primary care setting, the AUDIT is intended to be administered by a nurse or social worker (Babor et al., 2001) . It is administered by a registered nurse in the 
Medical record review
At the end of each baseline visit the research team reviews the patient's medical record to verify specific pieces of the medical history.
These variables of interest include CD4+ T cell count, CD4 nadir (i.e., lowest historical CD4 count), HIV viral load, prescribed ART, year of HCV diagnosis, HCV treatment history, HCV viral load, liver fibrosis level, HCV genotype, HCV appointment history, comorbidities, urine toxicology screening results if available, and health insurance status.
Health care utilization
In addition to baseline and outcome data collection, monthly activity logs are completed for each study participant, independent of allocated study arm. These data are collected from the study participant's electronic medical record and the research nurse case manager's notes.
The type, quantity, and content of all encounters with a study participant in the Johns Hopkins system are recorded each month, including nurse visits. This will define usual care for Bartlett Specialty Practice patients.
The type, quantity, and content of all Care2Cure study visits are also recorded to define the dose of the intervention.
Outcomes
Study outcomes (linkage to care and time to treatment initiation) are assessed using objective data extracted from the participant's medical record.
Linkage to care
For the primary outcome of linkage to care, the medical record is reviewed 60 days after the baseline visit to verify whether the participant attended one or more HCV Practice appointment since randomization (yes/no). All provider visits at the HCV Practice are registered in the electronic medical record, so absence of a registered appointment during the study period is considered non-attendance for the primary outcome variable.
Time to treatment initiation
To measure our secondary outcome of time to treatment initiation, the electronic medical record is reviewed 6 months after the baseline visit.
The study team collects multiple variables related to treatment initiation from the medical record, including whether a change in ART was made during the study period (yes/no), if a prescription for HCV therapy was written during the study period (yes/no and the drug ( Data on participant characteristics obtained in the baseline medical record abstraction are recollected at 6 months as well. These include HCV RNA, which will indicate whether a participant achieved sustained virologic response during the study period. Additional items related to specific barriers to HCV treatment referral, appointment scheduling, appointment attendance, and treatment initiation are also included in the 6-month medical record review.
| Data storage and monitoring
All data are collected and managed using REDCap electronic data capture tools hosted at Johns Hopkins University (Harris et al., 2009 ).
REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies, providing: (i) an intuitive interface for validated data entry; (ii) audit trails for tracking data manipulation and export procedures; (iii) automated export procedures for seamless data downloads to common statistical packages; and (iv) procedures for importing data from external sources. Randomization occurs directly in REDCap to ensure that the study team has no a priori knowledge of group assignment when enrolling study participants.
| Statistical analysis
Exploratory and descriptive analyses will be completed for all study variables. Variables will be inspected for normality and summarized with means and standard deviations or medians and interquartile ranges accordingly. Baseline characteristics of the two groups (enhanced usual care vs. NCM intervention) will be assessed. Any differences between the groups will be adjusted for in further analysis. The significance level will be set at .05. The primary (outcome) analysis will follow the principle of intentionto-treat.
The primary outcome is linkage to care, measured by attendance at the HCV Practice within 60 days of randomization (yes/no). The group difference in the primary outcome will be tested using a twosample z-test for the difference in proportions comparing the NCM intervention group to the enhanced usual care group. Binary logistic regression will be used to determine an effect of study arm on linkage to care controlling for differences in age, sex, race, HCV knowledge, substance use, liver fibrosis level, CD4+ T cell count, HIV viral load, and health insurance type.
The secondary outcome is time to HCV treatment initiation, measured by the number of days from randomization to the date the participant starts taking DAAs in the medical record. Kaplan Meier estimates will be computed to compare time to HCV treatment initiation between participants in the NCM intervention group and the enhanced usual care group, and a log-rank test will be used to examine the difference. Potential covariates (age, sex, race, HCV knowledge, substance use, liver fibrosis level, CD4+ T cell count, HIV viral load, and health insurance type) will be included in a Cox regression model. To account for a time to treatment initiation greater than the observed time period of 6 months, right censoring will be implemented for participants who have not initiated HCV treatment at the end of the 6-month period (Hosmer, Lemeshow, & May, 1999) .
To our knowledge, this is the first clinical trial to examine the effects of a nurse case management intervention to improve the HCV care continuum among people co-infected with HIV/HCV in the era of alloral DAAs. Given the acceleration of liver disease among people coinfected with HIV/HCV, timely treatment is essential, and DAAs make this possible (Bhattacharya et al., 2017; Lo Re et al., 2014) . The goals of the Care2Cure study are to increase the proportion of HIV/HCV coinfected adults who link to HCV care and decrease time to DAA initiation. The findings from this study will inform efforts to ensure that the most effective linkage to care and treatment approach are integrated into care of this population.
The Care2Cure study is designed to attend to the needs of hardto-reach patient populations. At the time this study was rolled out, the clinic had already linked the majority of its HIV/HCV co-infected patients to HCV care and achieved a cure in 43%, indicating that many patients who were immediately ready for HCV therapy and were ideal treatment candidates had already received HCV treatment in the first few years of DAA availability. The remaining population may be less engaged in their healthcare and/or more complex to treat, including those who inject drugs, drink alcohol, have mental health diagnoses, and may not be well engaged in HIV care, including patients not virally suppressed on ART. Our HCV NCM intervention is designed to improve care for these populations, and the sample enrolled is expected to reflect the real-world challenges of improving the HCV care continuum. This study will also help us to identify characteristics associated with, and barriers to, engaging in the HCV care continuum in a complex HIV co-infected population impacted by multiple barriers influenced by their social determinants of health.
| Challenges
The target population for the Care2Cure study introduces many challenges. Recruitment of patients who are not well engaged in health care into research is difficult, and many strategies have been employed in response to this challenge. We obtained IRB approval to mail letters to potentially eligible clinic patients who were scheduled for an upcoming HIV appointment to encourage them to attend their appointment and meet with research staff on the same day. We engaged providers in the clinic, who have trusting relationships with their patients, to refer eligible participants to our study. To attract more participants, we also increased compensation for the baseline study visit from $10 to $20. With these adjustments, we have enrolled 68 study participants and are continuing to collect data and implement the intervention.
Barriers to successful implementation of the intervention occur at the provider and payer levels. At the HIV provider level, hesitation to provide an HCV care referral for participants who have a detectable HIV viral load, are currently injecting drugs, or frequently miss HIV primary care appointments has led our research team to collaborate with the HCV Practice on a campaign to stress the ability to cure every patient, regardless of these stigmatizing factors. Insurance approval for DAAs has slowed time to treatment initiation and overall treatment initiation abilities, but our study team has worked with the pharmacy prior authorization team to minimize this barrier and refers participants to HCV research studies involving treatment to work around insurance approval.
| Strengths and limitations
Although we have overcome these challenges, the Care2Cure study has a few limitations worth noting. Self-reported assessments in the baseline questionnaire may be subject to desirability bias. However, the items and instruments chosen, including the AUDIT, for example, are widely used and regarded as valid and reliable measures of the concepts of interest. We also verify important health-related measures, including medications and lab values, in the medical record.
We are unable to control for external factors that may affect study results, such as change in clinic processes, change in state Medicaid reimbursement policies, FDA approval of new DAAs, and changes in HIV and HCV treatment guidelines. The HIV clinic moved 9 months into study recruitment and became co-located with the HCV Practice, which was expected to improve linkage to HCV care naturally within usual care. In addition to randomization, which ensures external factors are applied to both groups equally, we are documenting these contextual factors to help with interpretation of findings. Finally, given the fortunate and fairly unique situation of having a co-located HIV and HCV clinic, HIV patients in this setting may generally do better in engaging in HCV care than settings that do not have HCV resources, limiting the generalizability of the Care2Cure study. However, the NCM protocol is not specific to a co-located setting and can be translated to other settings for future studies.
This study does have several strengths as well. The intervention is theory-driven, and its components are based on prior effective interventions with similar populations (Andersen, 1995; Craw et al., 2008; Gardner et al., 2005) . The RCT design minimizes bias and baseline differences between groups, while also allowing causal relationships to be tested. Standard operating procedure manuals have been developed to maintain intervention fidelity and protect human subjects, including procedures for participants reporting depressive symptoms and alcohol dependence. Our outcome variables are objective measures and collected from the medical record by a study team member blinded to study arm assignment. Our primary outcome of linkage to care will have minimal to no missing data because HCV Practice visits are required to be entered in the electronic medical record. The study does not require extensive follow up with participants, which will enhance retention and feasibility. The NCM intervention is fairly low-intensity and is intended to be easily integrated into HIV primary care settings that already have nurse case managers.
| CONCLUSIONS
This study of HCV nurse case management will provide much-needed evidence for the feasibility and usefulness of this novel intervention.
Results of this trial will be important in informing clinical care and future research to improve the care continuum for people living with HIV and HCV, particularly as we reach to achieve the World Health 
